Tirzepatide vs Semaglutide: How Do They Compare?
Tirzepatide and semaglutide are both peptide medicines, so their active molecules are short chains of amino acids. Both affect appetite, blood sugar and digestion. Semaglutide activates the GLP-1 receptor, a receiving point on cells for one of the body's natural food-response signals. Tirzepatide activates that receptor and a second one called the GIP receptor.
In the main clinical trials that compared the medicines directly, tirzepatide produced larger average reductions in body weight and HbA1c. HbA1c is a blood test that reflects a person's average blood sugar over roughly the previous three months. The findings do not mean tirzepatide is better for every person or every medical purpose. The answer depends on the exact product, the condition being treated, the administration level tested and the result being measured.
The comparison at a glance
| Question | Semaglutide | Tirzepatide |
|---|---|---|
| What receptors does it activate? | GLP-1 | GIP and GLP-1 |
| Is it a peptide? | Yes | Yes |
| US brand examples | Ozempic, Wegovy and oral semaglutide products | Mounjaro and Zepbound |
| How current US products are taken | Injection and tablets | Injection |
| Main diabetes product | Ozempic and oral semaglutide products | Mounjaro |
| Main weight-management product | Wegovy | Zepbound |
| Direct obesity result | 13.7% average weight reduction in SURMOUNT-5 | 20.2% average weight reduction in SURMOUNT-5 |
| Direct diabetes result | About a 1.9 percentage-point average fall in HbA1c in SURPASS-2 | About a 2.0 to 2.3 percentage-point average fall in HbA1c at the levels tested in SURPASS-2 |
| Are they interchangeable? | No | No |
The brand names should not be used as though they describe the molecule in every form. Ozempic and Wegovy both contain semaglutide, but they are different finished medicines with different labels. Mounjaro and Zepbound both contain tirzepatide, but their approved uses also differ.
What are semaglutide and tirzepatide?
Both molecules were designed from natural hormones involved in the body's response to food.
GLP-1 and GIP are shortened names for two hormones released after eating. They help the body coordinate insulin, the hormone that helps move sugar from the blood into cells, as well as digestion and appetite signals to the brain. Semaglutide and tirzepatide have been changed so they break down more slowly and remain active for much longer than the natural hormones.
Semaglutide is called a GLP-1 receptor agonist. This means it attaches to and activates the cell receptor that normally receives the GLP-1 signal. It can increase insulin release when blood sugar is high, reduce glucagon, which is a hormone involved in raising blood sugar, slow stomach emptying and reduce appetite and food intake.
Tirzepatide activates the GIP receptor as well as the GLP-1 receptor. This is why it is described as a dual receptor agonist. Activating two receptors does not automatically make it better. The result also depends on how the medicine is built, how strongly it activates each receptor, how much reaches the body and the person taking it.
Put simply, semaglutide copies part of one natural hormone signal. Tirzepatide combines activity at two related receptors. Their effects overlap, but they are not the same medicine with different branding.
Is tirzepatide a GLP-1 medicine?
Yes, but it is not a GLP-1-only medicine.
Tirzepatide activates both the GLP-1 and GIP receptors. It is often grouped with GLP-1 medicines because that term is familiar and because the two molecules share several effects and side effects. More precisely, tirzepatide works through both hormone signals.
Semaglutide is a GLP-1 receptor agonist. Neither medicine is insulin, a stimulant or a steroid.
Which products are actually being compared?
Questions such as “Mounjaro vs Ozempic” or “Zepbound vs Wegovy” often mix the molecule with the brand.
| Active molecule | Product | Main approved uses in the current US label |
|---|---|---|
| Semaglutide | Ozempic | Type 2 diabetes, with certain approved uses for reducing heart and kidney risks |
| Semaglutide | Wegovy | Long-term weight management, heart-risk reduction in a defined population, and certain treatment uses for MASH, a serious form of fatty liver disease |
| Semaglutide | Oral products | Type 2 diabetes or weight management, depending on the finished product and label |
| Tirzepatide | Mounjaro | Type 2 diabetes, including an approved use for reducing heart and blood-vessel risk in a defined group |
| Tirzepatide | Zepbound | Long-term weight management and moderate-to-severe obstructive sleep apnoea, a condition involving repeated breathing problems during sleep, in eligible adults with obesity |
An approval applies to one finished version of a medicine, a particular group of patients and a particular use. It does not automatically apply to every product containing the same active molecule.
For example, Ozempic is widely associated with weight loss, but Wegovy is the semaglutide brand approved for weight management. Zepbound and Mounjaro contain the same active molecule, but Zepbound's approval for obstructive sleep apnoea does not make every tirzepatide product an approved sleep-apnoea medicine.
What did the direct weight-loss trial find?
SURMOUNT-5 is the most useful direct comparison for weight loss because it tested both medicines in the same trial. Participants were randomly assigned to one medicine or the other, which helps make the two groups more comparable at the start.
The trial included 751 adults with obesity, or overweight plus at least one weight-related condition. Participants did not have type 2 diabetes. They were assigned to tirzepatide or semaglutide for 72 weeks.
The trial was open-label, meaning that participants and researchers knew which medicine each person received. Body weight is an objective measurement, but knowing the treatment can still affect expectations, how closely people follow the trial plan, how they report side effects and whether they decide to stop.
Administration levels studied in SURMOUNT-5
| Trial group | Administration used in the study | Trial context |
|---|---|---|
| Tirzepatide | Once-weekly injection under the skin, increased under the study plan to the highest level each participant could tolerate, up to 10 mg or 15 mg | Participants did not all finish at the same level |
| Semaglutide | Once-weekly injection under the skin, increased under the study plan to the highest level each participant could tolerate, up to 1.7 mg or 2.4 mg | The later 7.2 mg Wegovy option was not part of this trial |
These are documented study levels, not recommendations for personal use. The trial used approved finished medicines, planned increases and clinical monitoring.
At week 72, average body weight had fallen by 20.2% in the tirzepatide group and 13.7% in the semaglutide group. Average waist circumference fell by 18.4 centimetres and 13.0 centimetres respectively.
Participants assigned to tirzepatide were also more likely to reach weight-loss thresholds of at least 10%, 15%, 20% and 25%.
This is strong evidence that tirzepatide produced greater average weight loss than the semaglutide treatment tested in this group. It does not show that every person will lose more with tirzepatide. It also does not compare tirzepatide with oral semaglutide, people with diabetes or the higher 7.2 mg Wegovy injection added later.
The study was funded by Eli Lilly, the manufacturer of tirzepatide. Industry funding does not make a result false, but readers should know who paid for a study when assessing its evidence.
The 2026 Wegovy update changes the simple comparison
SURMOUNT-5 compared tirzepatide with semaglutide at the highest level each participant could tolerate, up to 1.7 mg or 2.4 mg for semaglutide. In 2026, the US Wegovy label added a 7.2 mg weekly injection.
The label describes a separate 72-week study of 1,407 adults with obesity and without type 2 diabetes. Participants were randomly assigned to Wegovy 7.2 mg, Wegovy 2.4 mg or a placebo, an inactive comparison treatment containing no semaglutide. The label reports average weight changes of about 18.7%, 15.6% and 3.9% respectively, using its stated method for analysing the trial data.
The 18.7% average is closer to the tirzepatide result in SURMOUNT-5 than the earlier semaglutide figure was. However, the numbers came from separate trials. They do not show how 7.2 mg semaglutide and tirzepatide would compare in the same group of people.
The higher level also changed the side-effect picture. The label reports nausea, vomiting, constipation and changes in skin sensation among the side effects seen with 7.2 mg. A higher administration level may change both the average benefit and the side effects.
What we can say remains limited: tirzepatide outperformed the semaglutide treatment used in SURMOUNT-5. There has not yet been a direct trial comparing tirzepatide with the later 7.2 mg Wegovy product.
What did the direct diabetes trial find?
SURPASS-2 compared the medicines in 1,879 adults whose type 2 diabetes was not adequately controlled with metformin. Metformin is a widely used medicine that helps lower blood sugar in people with type 2 diabetes. The trial lasted 40 weeks.
Participants received once-weekly tirzepatide at a continuing level of 5 mg, 10 mg or 15 mg, or once-weekly semaglutide at 1 mg. The tirzepatide groups began at a lower level and increased gradually under the study plan.
At week 40, average HbA1c fell by about 2.0, 2.2 and 2.3 percentage points across the three tirzepatide groups, compared with about 1.9 points with semaglutide. HbA1c is itself reported as a percentage, so changes are described in percentage points. Average weight reductions were also greater with tirzepatide.
The trial first tested whether each tirzepatide level reduced HbA1c by at least as much as semaglutide 1 mg. All three then met the stricter statistical test for a greater reduction.
The result answers the specific question tested in 2021. It does not show that tirzepatide outperforms every current semaglutide level or product. It also cannot be used to convert one medicine into the other. A milligram of tirzepatide is not equivalent to a milligram of semaglutide.
Why separate trials are harder to compare
Before SURMOUNT-5, people often placed results from STEP 1 and SURMOUNT-1 side by side.
STEP 1 studied semaglutide 2.4 mg against a placebo for 68 weeks in 1,961 adults with overweight or obesity and without diabetes. Average weight change was 14.9% with semaglutide and 2.4% with placebo.
SURMOUNT-1 studied tirzepatide 5 mg, 10 mg and 15 mg against placebo for 72 weeks in 2,539 adults with overweight or obesity and without diabetes. Average changes were 15.0%, 19.5% and 20.9% with tirzepatide, compared with 3.1% with placebo.
The numbers look easy to compare, but they came from different participants, time periods and study rules. The researchers also used different methods to deal with missing results and people who stopped treatment, which can change the reported average.
Separate trials provide useful context. They cannot replace a trial that randomly assigns people to either medicine and compares them directly.
Which works better for weight loss?
At the administration levels tested in SURMOUNT-5, tirzepatide produced the larger average weight reduction. This is the clearest trial evidence comparing the two medicines directly.
“More average weight loss” is not the same as “better for every person”. An average combines people who lost much more, people who lost less, people who could not tolerate the medicine and people who stopped for other reasons.
The comparison changes as new versions of the medicines appear. The higher 7.2 mg Wegovy injection was not included in SURMOUNT-5. Results from a separate study suggest that it may reduce some of the numerical gap, but only a direct trial could provide a reliable comparison.
Which is better for type 2 diabetes?
SURPASS-2 favoured tirzepatide for average HbA1c and weight reductions when compared with semaglutide 1 mg. That is useful evidence, but diabetes care involves more than those two averages.
Evidence about heart and kidney outcomes may also matter. The choice can be affected by existing eye disease, digestive side effects, other medicines, how the product is taken, access and the person's wider medical history.
This guide explains the evidence. It cannot decide which prescription medicine is suitable for an individual.
How do their other approved uses compare?
The answer depends on the exact product and the group of patients covered by its approval.
Heart and blood-vessel outcomes
SELECT was the name of a large clinical trial involving 17,604 adults with overweight or obesity and existing cardiovascular disease, meaning disease affecting the heart or blood vessels. The participants did not have diabetes. The trial tested whether semaglutide could reduce major cardiovascular events: cardiovascular death, a non-fatal heart attack or a non-fatal stroke.
The SELECT results support Wegovy's approved use for reducing these events in certain adults with cardiovascular disease and overweight or obesity. Mounjaro's current label also includes reducing major cardiovascular events, but in adults with type 2 diabetes who are at high cardiovascular risk. Its evidence came from a different group of people and a different comparison.
Both products therefore have evidence concerning heart and blood-vessel outcomes, but their approved uses apply to different groups of people. It would be misleading to say that one has a “heart benefit” and the other does not.
What does SURPASS-CVOT actually show?
SURPASS-CVOT compared tirzepatide with dulaglutide, an established GLP-1 medicine, in adults with type 2 diabetes and atherosclerotic cardiovascular disease, meaning disease involving plaque in arteries. The double-blind trial's main outcome combined cardiovascular death, non-fatal heart attack and non-fatal stroke.
Events occurred in 12.2% with tirzepatide and 13.1% with dulaglutide. The hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01. A hazard ratio compares event rates over time; 1 represents no difference. The interval included 1, so superiority was not established. The trial met its prespecified non-inferiority criterion: tirzepatide was not worse by more than the accepted margin.
The main paper was published in December 2025. Its comparator and diabetes population differ from SELECT's placebo comparison in people without diabetes. Neither trial directly establishes which medicine prevents more events in the same population. Product approval and the statistical claim from a particular comparison should both be reported accurately.
Kidney outcomes
Ozempic has a specific approved use for reducing certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease, which means long-term damage that reduces how well the kidneys work.
This approved use does not automatically apply to every semaglutide product. It also does not prove that tirzepatide has no effects on the kidneys. It tells us what the current product labels are permitted to claim.
Obstructive sleep apnoea
Zepbound is approved to treat moderate-to-severe obstructive sleep apnoea in eligible adults with obesity. Sleep apnoea is a condition in which breathing repeatedly stops or becomes restricted during sleep. Semaglutide does not have the same specific US product approval.
MASH
Wegovy injection has accelerated approval for certain adults with metabolic dysfunction-associated steatohepatitis, or MASH. This is a serious form of fatty liver disease in which fat buildup causes inflammation and damage. The approval covers people with moderate-to-advanced liver scarring, called fibrosis, who have not developed cirrhosis, the most advanced stage of liver scarring.
The FDA's accelerated approval route allows a medicine to be approved because it improves a measurement expected to predict a clinical benefit, while longer-term benefits are still being confirmed. Continued approval may depend on further evidence. This approval should not be extended to every form of fatty liver disease or every semaglutide product.
Children and adolescents
Age limits also differ by product and condition. Current US labels include Mounjaro for type 2 diabetes from age 10 and Wegovy injection for weight management from age 12. Zepbound's current approved uses are for adults.
How do the side effects compare?
The most common side effects overlap because both medicines affect related hormone signals and slow parts of digestion.
Common effects reported across products include:
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Abdominal discomfort
- Reduced appetite
These effects are often most noticeable while the administration level is being increased. Not everyone experiences them, and two people using the same labelled level may respond differently.
SURMOUNT-5 found that digestive side effects were the most common in both groups. Most were mild or moderate and occurred mainly while administration levels were being increased. The trial aimed for the highest level each person could tolerate, so not every participant reached or stayed at the highest level allowed.
There is no single answer to which medicine causes more side effects. Trials report averages across groups, but the side effects an individual can tolerate vary from person to person and between finished products.
What serious risks and warnings do they share?
Both product families have important safety warnings. Depending on the product, these include:
- A boxed warning, the FDA's strongest type of safety warning, about tumours in a specific type of thyroid cell called a C-cell. These tumours were seen in rodents, and it is not known whether the same risk applies to humans
- A warning that the medicines should not be used by people with a personal or family history of medullary thyroid carcinoma, a rare type of thyroid cancer, or multiple endocrine neoplasia syndrome type 2, an inherited condition that raises the risk of certain hormone-related tumours
- Acute pancreatitis, meaning sudden inflammation of the pancreas
- Gallbladder disease
- Kidney injury related to severe fluid loss or dehydration
- Severe digestive reactions
- Allergic reactions
- Low blood sugar when combined with insulin or medicines that increase insulin release
- Delayed stomach emptying, which can affect oral medicines and procedures using drugs that make a person unconscious or deeply sedated
- Pregnancy-related warnings
There are also product-specific differences. Tirzepatide labels warn that oral hormonal contraceptives, such as the birth-control pill, may become less effective when treatment begins and after each increase because the stomach empties more slowly. Semaglutide labels warn about complications of diabetic retinopathy, which is damage to blood vessels at the back of the eye. The concern is greater when blood sugar improves quickly in someone who already has this eye disease.
The current higher-level Wegovy data also report changes in skin sensation more often at 7.2 mg than at 2.4 mg.
Although the medicines affect some of the same pathways, their safety warnings are not identical. The current prescribing information for the exact product is the relevant source.
Can semaglutide and tirzepatide be combined?
They should not be combined or “stacked” as though one simply adds something missing from the other.
Zepbound's label states that it should not be used with another tirzepatide-containing product or with a GLP-1 receptor agonist. Taking tirzepatide and semaglutide together would make both medicines activate the GLP-1 pathway at the same time. There is no approved evidence showing that this is safe or adds a benefit.
The same caution applies to switching. Equal milligram amounts are not equivalent, and there is no valid milligram-for-milligram conversion. Switching between prescription medicines is a decision for a qualified healthcare professional, not a calculator problem.
This guide does not provide a switching schedule, an overlap period or instructions about how long to wait between the medicines.
Why can real-world results be smaller than trial results?
Clinical trials select participants using detailed rules. They provide regular follow-up, planned support with eating and physical activity, carefully controlled increases and active efforts to keep participants in the study.
Everyday treatment is less controlled. Cost, supply, side effects, missed appointments, using a lower level because of side effects and stopping treatment can all change the result. People may also have more complicated medical histories than trial participants.
Trial averages are evidence of what happened under the trial conditions. They are not promises of what will happen to an individual.
What happens after treatment stops?
Neither medicine should be understood as a short course that permanently resets weight.
In a follow-up to STEP 1, participants regained much of the weight they had lost during the year after semaglutide and the trial's support programme ended. Tirzepatide research has also found weight regain when the medicine was replaced with a placebo. People who continued treatment maintained or extended their average weight loss.
These findings support understanding obesity as a chronic condition. They do not mean treatment must continue in every case, and they do not provide instructions for starting or stopping a prescribed medicine.
Approved medicines are not the same as research products
The evidence in this guide comes from quality-controlled finished medicines used in monitored clinical trials.
A vial or powder labelled “semaglutide” or “tirzepatide” is not automatically Ozempic, Wegovy, Mounjaro or Zepbound. The name alone does not prove what is inside, how strong it is, whether it contains contaminants, whether it is sterile or whether it remains stable.
Compounded products and research-labelled materials should not be assumed to produce the same results as approved pens or tablets. Administration levels from clinical trials must not be converted into instructions for an unapproved product.
So, which one is better?
Tirzepatide produced larger average weight and HbA1c reductions in the two major direct trials. This is a meaningful result, but it does not mean tirzepatide wins every possible comparison.
Those trials tested specific semaglutide products and administration levels. Semaglutide is now available in oral and injectable products, including a higher Wegovy injection introduced after SURMOUNT-5. Particular semaglutide products also have evidence and approvals relating to cardiovascular disease, chronic kidney disease and MASH.
Tirzepatide has its own evidence and approvals in diabetes, reducing heart and blood-vessel risk, obesity and obstructive sleep apnoea.
For an individual, the comparison needs to include the purpose of treatment, the health outcomes studied, side effects, medical history, how the medicine is taken and access. A qualified prescriber can assess these factors together.
For a deeper introduction to each molecule, read What Is Semaglutide? and Is Tirzepatide a Peptide?.
Frequently asked questions
Is tirzepatide the same as semaglutide?
No. Both activate the GLP-1 receptor, but tirzepatide also activates the GIP receptor. They are different peptide molecules, and equal milligram amounts cannot be treated as equivalent.
Is tirzepatide stronger than semaglutide?
Tirzepatide produced larger average weight and HbA1c reductions in direct trials against the semaglutide levels tested. “Stronger” is not a helpful medical comparison because it could mean a larger effect, greater receptor activity or more side effects.
Which caused more weight loss in SURMOUNT-5?
Average weight change at 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide. These are group averages from adults with obesity or overweight without type 2 diabetes.
What administration levels were studied in SURMOUNT-5?
The trial used maximum tolerated once-weekly levels of 10 mg or 15 mg for tirzepatide and 1.7 mg or 2.4 mg for semaglutide. These are descriptions of the study, not personal dosing advice.
Did SURMOUNT-5 test the 7.2 mg Wegovy injection?
No. That higher-level semaglutide product appeared after SURMOUNT-5. Results from its separate study cannot establish how it compares directly with tirzepatide.
Which performed better for HbA1c in SURPASS-2?
All three tirzepatide levels produced somewhat larger average HbA1c reductions than semaglutide 1 mg at week 40. The study did not compare tirzepatide with every current semaglutide option.
Is Ozempic the same as Wegovy?
They contain semaglutide, but they are different finished medicines with different ingredients, ways of being supplied and approved uses.
Is Mounjaro the same as Zepbound?
They contain tirzepatide, but the products have different approved uses. The names should not be treated as interchangeable in a discussion of approvals.
Can tirzepatide and semaglutide be taken together?
Their labels do not support combining them. Zepbound specifically should not be used with another tirzepatide product or another medicine that activates the GLP-1 receptor.
Which medicine has evidence about heart and blood-vessel outcomes?
Both now have evidence and approved uses relating to heart and blood-vessel outcomes, but for different groups of people. Wegovy's approval includes certain adults with existing cardiovascular disease and overweight or obesity. Mounjaro's approval applies to adults with type 2 diabetes who are at high cardiovascular risk.
Which one has fewer side effects?
There is no universal answer. Digestive side effects are common with both, but people tolerate them differently. The exact product, administration level, how quickly it is increased, other medicines and individual biology can all affect the experience.
Can clinical-trial results be applied to compounded products?
No. Approved trial medicines are made under controlled conditions and have known ingredients, strength, purity, stability and delivery systems. An unapproved or compounded product may not share those features.
Sources
Research reviewed through 2 November 2026.